CVKD · Cadrenal Therapeutics, Inc. · Executive Compensation
$0.85
-0.06 (-6.61%)
At close · Oct 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$3.25M
Shares
3.57M
Volume · Oct 12
87.66K
Avg daily vol (3M)
453.56K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Quang X. Pham | Chief Executive Officer | $1,909,694 |
| James Ferguson | Former Chief Medical Officer | $1,395,809 |
| Matthew Szot | Former Chief Financial Officer | $1,307,019 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Quang X. Pham | Chief Executive Officer | $1,223,381 |
| Matthew Szot | Chief Financial Officer | $868,279 |
| Jeffrey Cole | Chief Operating Officer | $726,301 |
| James Ferguson | Former Chief Medical Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Quang Pham | Chief Executive Officer | $967,000 |
| Quang X. Pham | Chief Executive Officer | $967,000 |
| Matthew Szot | Chief Financial Officer | $844,890 |
| Douglas Losordo | Chief Medical Officer | $528,690 |
| Jeffrey Cole | Chief Operating Officer | $24,875 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Quang Pham | Chief Executive Officer | $816,223 |
| Douglas Losordo | Chief Medical Officer | $648,560 |
| Matthew Szot | Chief Financial Officer | $359,605 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Quang X. Pham | Class I director | Appointed | 2026-09-29 |
| James J. Ferguson III | Chief Medical Officer | Resigned | 2026-07-17 |
| James J. Ferguson III | Chief Medical Officer | Resigned | 2026-07-10 |
| Glynn Wilson | Class I director | Resigned | 2026-06-29 |
| Glynn Wilson | Class III director | Appointed | 2026-06-29 |
| Steven Zelenkofske | Class III member of the Board | Resigned | 2026-06-29 |
| John P. Sharp | Interim Chief Financial Officer | Appointed | 2026-06-29 |
| Quang X. Pham | interim Chief Financial Officer | Appointed | 2026-06-03 |
| Quang X. Pham | interim Principal Accounting Officer | Appointed | 2026-06-03 |
| Matthew K. Szot | Chief Financial Officer | Terminated | 2026-06-03 |
| Lee Scott Golden, M.D. | Class II director | Appointed | 2025-12-01 |
| Robert Lisicki | Class II Director | Resigned | 2025-07-18 |
| James J. Ferguson, MD | Chief Medical Officer | Appointed | 2025-02-07 |
| Douglas Losordo | Chief Medical Officer | Terminated | 2025-02-07 |
| James J. Ferguson III | Chief Medical Officer | Appointed | 2025-02-07 |
| Robert Lisicki | Class II director | Appointed | 2024-07-31 |
| John Murphy | Class II director | Appointed | 2024-07-31 |
| Jeffrey Cole | Chief Operating Officer | Appointed | 2024-02-12 |
| Robert Lisicki | Class II director | Appointed | 2023-07-24 |
| Matthew K. Szot | Chief Financial Officer | Appointed | 2023-01-25 |
| John Murphy | Class II director | Appointed | 2023-01-25 |
| Steven Zelenkofske | Class III director | Appointed | 2023-01-25 |
| Glynn Wilson | Class I director | Appointed | 2023-01-25 |